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STAT1 activation in association with JAK2 exon 12
mutations
JAK2 exon 12 mutations are associated with more
marked and isolated erythrocytosis than JAK2V617F. We
analyzed expression profiles of JAK2 exon 12-mutant and
wild-type erythroid colonies from patients with poly-
cythemia vera (PV). Exon 12 mutations were associated
with interferon-target gene upregulation, STAT1 activa-
tion and additional gene expression changes that were
quantitatively and qualitatively similar to those in
JAK2V617F-heterozygous cells from essential thrombo-
cythemia (ET) patients. These results demonstrate that
JAK2 exon 12-mutated PV does not reflect attenuated
STAT1 signaling, and that transcriptional consequences
of JAK2 mutations are remarkably similar in JAK2 exon
12-mutated PV and JAK2V617F-positive ET. 
JAK2 exon 12 mutations are found in most patients
with JAK2V617F-negative PV,1,2 but unlike JAK2V617F,
have never been reported in ET. Compared to PV patients
with JAK2V617F, patients with exon 12 mutations have
higher hemoglobin concentrations, lower white cell and
platelet counts, and isolated bone marrow erythroid
hyperplasia.1,3 Similar phenotypic differences were seen
between retroviral murine bone marrow transplantation
models carrying exon 12 mutant and V617F alleles.1
These differences raise the question of how the signaling
consequences of JAK2V617F and exon 12 mutations dif-
fer. 
Exon 12 mutations, like V617F, are associated with
constitutive, erythropoietin-independent activation of
JAK2, STAT5 and ERK1/2.1 Overexpression experiments
in some,1 but not other,4 cell lines suggested that these
mutations might be associated with more marked activa-
tion of JAK2 than V617F. The concept that the pro-
nounced PV phenotype associated with exon 12 muta-
tions may reflect the strength of JAK2 activation is also
consistent with evidence that JAK2V617F homozygosity
results in a PV (rather than ET) phenotype.5,6 However,
the signaling consequences of exon 12-mutant JAK2 have
not been examined in patient cells. Moreover, the obser-
vations that JAK2V617F-heterozygous cells from PV
patients show attenuated STAT1 activation compared to
those with ET,7 and that impaired STAT1 signaling can
contribute to a PV phenotype,7,8 raise the question of
whether reduced STAT1 activation is a feature of exon
12-mutated PV. We therefore studied the transcriptional
signature of exon 12 mutations in erythroid colonies
from PV patients. 
Patients were recruited from seven centers (Online
Supplementary Appendix) and met British Committee for
Standards in Haematology diagnostic criteria; for clinical
features see Table 1 and Online Supplementary Table S1.
For 13 patients with JAK2 exon 12-mutated PV, we com-
pared genome-wide RNA profiles of JAK2-mutant and
wild-type erythroid colonies grown from a single patient
in the same culture plate (Figure 1A). This paired
approach controls for factors including age, gender, treat-
ment, germline genetic background and experimental
conditions.7 BFU-E colonies were cultured from peripher-
al blood as previously described5 using 0.1 U/mL erythro-
poietin (at which concentration known JAK2-target
genes show differential expression between wild-type
and JAK2-mutant cells7). Colonies were pooled by geno-
type and RNA analyzed using Illumina Human-12 v.4.0
Expression BeadChips (Online Supplementary Appendix).
Unsupervised clustering of global expression profiles
showed that mutant colonies were generally most similar
to wild-type colonies from the same patient (Figure 1B),
demonstrating that the transcriptional changes associated
with JAK2 exon 12 mutations are subtle. These data con-
firm the importance of comparing mutant and wild-type
colonies from the same patient to control for inter-indi-
vidual variation in gene expression. 
Most patients with JAK2V617F-positive PV harbor
large homozygous-mutant erythroid clones. By contrast,
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Table 1. Samples from JAK2 exon 12-mutated PV patients used for microarray analysis.
Patient code Mutation Age Gender Therapy Samples
WT Het Hom
PX1 F537-K539delinsL 59 F VS 1 1 0
PX2 N542-E543del 38 F AG 2 2 0
PX3 H538QK539L 33 M VS 1 2 0
PX4 F537-K539delinsL 66 F VS 1 1 1
PX5 F537-F547dup11 81 F VS 1 1 0
PX6 H538-K539delinsL 64 M HC 1 1 0
PX7 N542-E543del 70 M HC 1 1 0
PX8 N542-E543del 42 M VS 2 2 0
PX9 N542-E543del 73 M VS, HC 1 1 0
PX10 F537-I546dup10+F547L 45 F VS, IFN 2 2 0
PX11 N542-E543del 33 F VS 1 1 1
PX12 N542-E543del 83 F VS 1 1 1
PX13 K539L 43 F VS 1 1 0
Therapy refers to that used at the time of colony assay, abbreviated as VS: venesection; HC: hydroxycarbamide; IFN: interferon-alfa or AG: anagrelide. The number of samples
used in the microarray analysis is shown, according to whether these were wild-type (WT), heterozygous (Het) or homozygous (Hom) for JAK2 exon 12 mutations. Where 2
samples were used for one genotype, these were independent pools of colonies collected from the same colony experiment. These pairs, and heterozygous- and homozygous-




Figure 1. Identification of transcriptional changes in JAK2 exon 12-mutant erythroid cells by clonal analysis. (A) Strategy for sample collection and processing.
BFU-E colonies were grown in methylcellulose medium at 0.1 U/mL erythropoietin for 14-16 days, plucked and genotyped for JAK2 exon 12 mutations. Colonies
were pooled by genotype and processed for RNA extraction, microarray analysis and validation. JAK2-mutant and wild-type colonies showed no consistent dif-
ferences in macroscopic or cytological morphology, or in differentiation stages as assessed by flow cytometry for CD71 and GpA (data not shown). (B)
Unsupervised hierarchical clustering of microarray datasets from wild-type and mutant colonies for 13 patients with JAK2 exon 12 mutations, performed using
the lumi package in R. See Table 1 for patient codes. Wild-type and heterozygous-mutant samples are denoted WT and Mut; where wild-type, heterozygous- and
homozygous-mutant samples were analyzed, these are denoted WT, Het and Hom, respectively. Where duplicates were analyzed for a genotype these are denot-
ed WT1/WT2 or Mut1/Mut2. (C) Expression levels of 11 genes, measured in cDNA from BFU-E colonies from PV patients with JAK2 exon 12-heterozygous
colonies and ET patients with JAK2V617F-heterozygous colonies by Fluidigm real-time PCR. Colonies were grown at 0.1 U/mL erythropoietin. Data were normal-
ized to a house-keeping gene (HPRT1) and expressed as fold change between expression in mutant and wild-type samples. Histograms show mean +/- SEM.
There were no significant differences between fold changes in the JAK2 exon 12-mutant PV and JAK2V617F-positive ET samples (Student’s t test, P>0.05 all
genes). (D) Sample GSEA plots and q values for gene sets where stimuli showed a positive association with mutant samples. In the whole analysis, 15 gene
sets indicated an association of the mutant genotype with interferon treatment, 13 with viral infection, 13 with treatment with cytotoxic agents and 3 with UV
exposure (Online Supplementary Table S3). These include gene sets up-regulated by the stimulus that were enriched in mutant samples and gene sets down-





erythroid colonies from patients with JAK2V617F-posi-
tive ET and exon 12-mutant PV are predominantly het-
erozygous-mutant.5 Despite this similarity, patients with
exon 12-mutant PV and JAK2V617F-positive ET show
markedly different clinical phenotypes. We therefore
focused on these two groups of patients to investigate the
signaling differences responsible for these phenotypes.
We initially analyzed the transcriptional consequences of
exon 12 mutations. Using a pairwise analysis, 66 genes
showed differential expression between JAK2 exon 12-
mutant and wild-type samples (46 genes up-regulated, 20
genes down-regulated in mutant samples; q<0.1, fold
change ≥1.25; Online Supplementary Table S2). Eleven
genes were selected for validation based on possible roles
in hematopoiesis, cell cycle or other processes relevant to
neoplasia (ADA, CEBPB, ESR2, FAM83A, FBXO6, GDF15,
LMO4, PARP3, STK19, TINF2, KIT; for references see
Online Supplementary Appendix). Real-time PCR using the
Fluidigm BioMark system (Fluidigm, CA, USA) (Online
Supplementary Appendix) confirmed differential expres-
sion for all 11 genes (Figure 1C). Interestingly, when the
expression changes in JAK2 exon 12-heterozygous
colonies from 6 PV patients were compared with those in
JAK2V617F-heterozygous colonies from 6 ET patients,
there were no significant differences in the fold changes
associated with the two mutation types for any of these
11 genes (Figure 1C). Moreover, an additional 15 of the
genes showing differential expression in exon 12-mutant
colonies in the microarray analysis (10 up-regulated, 5
down-regulated) were also identified in an analysis of
published microarray datasets from JAK2V617F-het-
erozygous colonies7 (Online Supplementary Table S2).
These findings demonstrate that the transcriptional
changes associated with JAK2V617F and JAK2 exon 12
mutations in human erythroblasts are remarkably similar,
with no differences in quantitative or qualitative expres-
sion detected between the mutations in validation exper-
iments. 
We next investigated the pathways perturbed in JAK2
exon 12-mutant erythroid cells using Gene Set
Enrichment Analysis (GSEA).9 Seventy-four gene sets
showed enrichment in mutant samples and 83 gene sets
in wild-type samples (q<0.1) (Online Supplementary Table
S3). Mutant samples showed enrichment for STAT5 tar-
gets (Figure 1D), indicating, as expected, that JAK2 exon
12 mutations are associated with STAT5 activation in
erythroblasts. The most frequent gene sets showing asso-
ciation with mutant samples were those for interferon
(IFN) treatment (15 gene sets), viral infection (13 gene
sets), cytotoxic agents (13 gene sets), UV exposure (3
gene sets) and p53/p21 target genes (3 gene sets) (Figure
1D and Online Supplementary Table S3). Similar observa-
tions have been made in JAK2V617F-heterozygous cells
from ET patients: upregulation of IFN target genes was
associated with STAT1 activation7 and upregulation of
genes induced by cytotoxics, UV exposure or DNA dam-
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Figure 2. STAT1 activation in association with JAK2 exon 12 mutations. (A) Expression levels of 8 IFNγ target genes11 measured in cDNA from BFU-E colonies
from polycythemia vera (PV) patients with JAK2 exon 12-heterozygous colonies and essential thrombocythemia (ET)  patients with JAK2V617F-heterozygous
colonies, using Fluidigm real-time PCR. Colonies were all grown at 0.1 U/mL erythropoietin. Data were normalized to a housekeeping gene (HPRT1) and
expressed as fold change between expression in mutant and wild-type samples. Histograms show mean +/- SEM. (B) Western immunoblot analyses for phos-
pho-STAT1 (tyrosine-701) of JAK2-null γ2A cells mock transfected or transfected with expression vectors for murine wild-type Jak2, Jak2K539L or Jak2V617F.
The experiment was performed twice and representative results are shown. (C) Intracellular flow cytometry for phospho-STAT5 (pSTAT5, tyrosine-694) and phos-
pho-STAT1 (pSTAT1, tyrosine-701) in BFU-E colonies. Colonies were pooled by genotype and erythroblasts gated on forward scatter and side scatter. Histograms
for wild-type and mutant colonies are shown for pSTAT5 (left) and pSTAT1 (right) for patient PX12 (upper panel). Median fluorescence intensity ratios (relative to




age was associated with DNA replication stress in
JAK2V617F-positive cells.10 Overall, 77 of the 157
enriched gene sets from the exon 12 analysis were also
identified in a GSEA of datasets from JAK2V617F-het-
erozygous samples7 (Online Supplementary Table S3), con-
firming that exon 12 and V617Fmutations cause upregu-
lation of similar pathways in erythroblasts.
The striking enrichment for IFN-related gene sets in
JAK2 exon 12-mutant cells (Figure 1D) was of particular
significance. JAK2 exon 12 mutations are associated with
an extreme PV phenotype (marked erythrocytosis, mini-
mal thrombocytosis).1,3 However, we previously showed
that JAK2V617F-mediated activation of STAT1, which is
preserved in JAK2V617F-mutant erythroblasts of patients
with ET, is impaired in those with JAK2V617F-positive
PV.7 Moreover, functional experiments in human cells7
and transgenic mice8 suggested that attenuated activation
of STAT1, which acts downstream of the IFNγ receptor
and JAK2, might contribute to the more pronounced ery-
throcytosis in PV compared to ET. Upregulation of eight
IFNγ-inducible genes11 was validated by real-time PCR in
colonies from 6 JAK2 exon 12-mutant PV patients and 6
JAK2V617F-positive ET patients (Figure 2A). Although
fold changes were variable amongst the exon 12-mutant
patients (perhaps reflecting signaling variation between
different mutations), they were at least as large as those
in JAK2V617F-positive samples. These data demonstrate
that interferon target genes are up-regulated in JAK2
exon 12-heterozygous erythroblasts to a similar extent as
that in JAK2V617F-heterozygous cells from ET patients.
We next asked whether upregulation of IFN target
genes in JAK2 exon 12-mutant cells reflects STAT1 acti-
vation. Expression of either Jak2K539L or Jak2V617F in
JAK2-null γ2A cells (Online Supplementary Appendix) was
associated with marked phospho-STAT1 activation com-
pared to wild-type Jak2 (Figure 2B). To investigate
whether STAT1 activation also occurs in human ery-
throid cells, erythroid colonies from 3 exon 12-mutated
PV patients and 2 JAK2V617F-positive ET patients were
analyzed by intracellular flow cytometry (Online
Supplementary Appendix). All patients showed small but
consistent increases in phospho-STAT5 and phospho-
STAT1 expression in mutant compared to wild-type cells,
which were similar in magnitude between JAK2 exon 12-
mutated PV and  JAK2V617F-positive ET samples (Figure
2C). The changes were modest, which is in keeping with
previous studies using phosFlow to measure pSTAT
changes in JAK2-mutant primary cells.12 These data
demonstrate that JAK2 exon 12 mutations are associated
with STAT1 activation in human erythroid cells, to a sim-
ilar extent to that induced by JAK2V617F in ET. Although
impairment of mutant JAK2-induced STAT1 activation
was previously observed in JAK2V617F-positive PV,7 this
impairment is not necessary for a marked erythrocytosis,
nor does it account for this phenotype in JAK2 exon 12-
mutated PV. 
In summary, we find the transcriptional consequences
of JAK2 exon 12 mutations in clonal erythroblasts from
PV patients to be indistinguishable from those of het-
erozygous JAK2V617F in ET. In contrast to JAK2V617F-
positive PV, patients with exon 12 mutations show no
evidence of attenuated STAT1 activation, demonstrating
that this impairment is not necessary for an erythrocyto-
sis. There is now evidence that other mechanisms, such
as JAK2V617F homozygosity, additional mutations,
mutational order and constitutional factors may con-
tribute to the phenotype of JAK2V617F-positive PV.6,13-15
STAT1 activation has been associated with enhanced
megakaryopoiesis and may contribute to the thrombocy-
tosis observed in 20% of patients with exon 12 muta-
tions,3 whilst absence of thrombocytosis in others may
reflect STAT1-independent mechanisms such as acceler-
ated platelet destruction.6 Taken together our data sup-
port the concept that the development of a PV or ET phe-
notype reflects combinations of mechanisms that operate
differently between individuals, and that, furthermore,
these mechanisms differ between classes of JAK2 muta-
tion. 
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